New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dextran 40 10%; glucose monohydrate 5% - solution for infusion - active: dextran 40 10% glucose monohydrate 5%

New Zealand - English - Medsafe (Medicines Safety Authority)

paragon care group new zealand limited t/a rem systems - dextran 40 10%; glucose monohydrate 5% - solution for infusion - active: dextran 40 10% glucose monohydrate 5%

Ireland - English - HPRA (Health Products Regulatory Authority)

baxter healthcare limited - dextran 40 glucose - solution for infusion - 10/5 %w/v %w/v

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - dextran 40 10%; glucose monohydrate 5% - solution for infusion - 10%/5% - active: dextran 40 10% glucose monohydrate 5%

United States - English - NLM (National Library of Medicine)

trigen laboratories, inc. - benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - benazepril hydrochloride 5 mg - benazepril hydrochloride tablets, usp are indicated for the treatment of hypertension. benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. benazepril hydrochloride tablets are contraindicated in patients who are hypersensitive to benazepril or to any other ace inhibitor. benazepril hydrochloride tablets are also contraindicated in patients with a history of angioedema with or without previous ace inhibitor treatment.

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

b. braun - dextran 40 - solution for infusion - 10 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

kuwait saudi pharmaceutical industries, kuwait - dextran 40 - solution for infusion - 10 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

b. braun - dextran 40 - solution for infusion - 10 %

United States - English - NLM (National Library of Medicine)

hospira, inc. - dextran 40 (unii: k3r6zdh4du) (dextran 40 - unii:k3r6zdh4du) - dextran 40 10 g in 100 ml - lmd (dextran 40) is indicated for use in the adjunctive treatment of shock or impending shock due to hemorrhage, burns, surgery or other trauma. it is not indicated as a replacement for whole blood or blood components if they are available. it should not replace other forms of therapy known to be of value in the treatment of shock. lmd is also indicated for use as a priming fluid, either as a sole prime or as an additive, in pump oxygenators during extracorporeal circulation. lmd is also indicated for use in prophylaxis of venous thrombosis and pulmonary embolism in patients undergoing procedures known to be associated with a high incidence of thromboembolic complications, such as hip surgery. lmd (dextran 40) is contraindicated in patients with known hypersensitivity to dextran, in those with marked hemostatic defects of all types (thrombocytopenia, hypofibrinogenemia, etc.) including those caused by drugs (heparin, warfarin, etc.), marked cardiac decompensation and in renal disease with severe oliguria or a

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - dextran 40 10%; sodium chloride 0.9% - solution for infusion - active: dextran 40 10% sodium chloride 0.9%